Covishield vaccine induces robust immune responses in Bangladeshi adults

[1]  R. Arbel,et al.  Effectiveness of the BNT162b2 Vaccine after Recovery from Covid-19 , 2022, The New England journal of medicine.

[2]  S. Arifeen,et al.  Seroprevalence of SARS-CoV-2 antibodies in Bangladesh related to novel coronavirus infection , 2022, IJID Regions.

[3]  A. Azman,et al.  SARS-CoV-2 Seroprevalence before Delta Variant Surge, Chattogram, Bangladesh, March–June 2021 , 2022, Emerging infectious diseases.

[4]  Huynh Ngoc Phuoc,et al.  Reactogenicity and immunogenicity of heterologous prime-boost immunization with COVID-19 vaccine , 2022, Biomedicine & Pharmacotherapy.

[5]  B. Pulendran,et al.  Disease characteristics and serological responses in patients with differing severity of COVID-19 infection: A longitudinal cohort study in Dhaka, Bangladesh , 2022, PLoS Neglected Tropical Diseases.

[6]  G. Screaton,et al.  Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study , 2022, The Lancet.

[7]  A. Kabir,et al.  Antibody Response to ChAdOx1-nCoV-19 Vaccine Among Recipients in Bangladesh: A Prospective Observational Study , 2021, Infection and drug resistance.

[8]  N. Gupta,et al.  Effectiveness of ChAdOx1 nCoV-19 vaccine against SARS-CoV-2 infection during the delta (B.1.617.2) variant surge in India: a test-negative, case-control study and a mechanistic study of post-vaccination immune responses , 2021, The Lancet Infectious Diseases.

[9]  A. Copas,et al.  Profile of humoral and cellular immune responses to single doses of BNT162b2 or ChAdOx1 nCoV-19 vaccines in residents and staff within residential care homes (VIVALDI): an observational study , 2021, The Lancet Healthy Longevity.

[10]  E. Callaway.  Mix-and-match COVID vaccines trigger potent immune response , 2021, Nature.

[11]  M. Snape,et al.  Heterologous prime-boost COVID-19 vaccination: initial reactogenicity data , 2021, The Lancet.

[12]  S. Madhi,et al.  Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant , 2021, The New England Journal of Medicine.

[13]  M. Knoll,et al.  Oxford–AstraZeneca COVID-19 vaccine efficacy , 2020, The Lancet.

[14]  Nguyen H. Tran,et al.  Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK , 2020, Lancet.

[15]  Nguyen H. Tran,et al.  Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. , 2020, Lancet.

[16]  A. Iafrate,et al.  Persistence and decay of human antibody responses to the receptor binding domain of SARS-CoV-2 spike protein in COVID-19 patients , 2020, Science Immunology.

[17]  S. Calderwood,et al.  Antibody responses after COVID-19 infection in patients who are mildly symptomatic or asymptomatic in Bangladesh , 2020, International Journal of Infectious Diseases.

[18]  A. Rodríguez-Morales,et al.  An update on SARS-CoV-2/COVID-19 with particular reference to its clinical pathology, pathogenesis, immunopathology and mitigation strategies , 2020, Travel Medicine and Infectious Disease.